GlobeNewswire Inc.··Pomerantz LlpAardvark Therapeutics Stock Plummets 56% as Law Firm Probes Cardiac Safety Concerns
Pomerantz Law Firm investigates Aardvark Therapeutics after Phase 3 trial pause over cardiac safety issues. Stock crashed 56.2% to $5.47.
AARDsecurities fraudclass action lawsuit